Global Antinuclear Antibody Test Market Revenue Grows at a CAGR of 13.38%

Introduction

Straits Research released its highly anticipated report, “Global Antinuclear Antibody Test Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 2.10 billion in 2025 and is anticipated to grow till USD 6.48 billion by 2034, growing at a CAGR of 13.38% from 2026-2034.

Market Dynamics

The market is driven by rising adoption of comprehensive autoantibody profiling across rheumatology and multidisciplinary care settings, where clinicians increasingly request broader antibody panels to support earlier evaluation of complex immune-mediated conditions. A restraint arises from variation in laboratory expertise and interpretation consistency across regions, which limits uniform testing quality and slows wider adoption of advanced platforms in decentralized facilities. An opportunity emerges from the expansion of digital immunology networks and centralized review hubs that support large population screening programs, encouraging healthcare systems to invest in high-throughput platforms and integrated software solutions that enhance autoimmune diagnostic capacity across diverse care environments.

Key Highlights

• Product: Based on Product, reagents & assay kits dominated the market with a revenue share of 47.81%.
• Technique: Based on Technique, the Immunofluorescence Assay segment dominated the market with a 53.45% share in 2025.
• Application: By Application, the Rheumatoid Arthritis segment held the dominant share of 34.72% in 2025.
• End Use: By End Use, the Hospitals segment dominated with a 42.34% share in 2025.
• Regional Insights: North America held a dominant share of the global market, accounting for 42.78%.

Competitive Players

1. Thermo Fisher Scientific Inc.
2. Bio-Rad Laboratories, Inc.
3. EUROIMMUN
4. Werfen
5. ZEUS Scientific, Inc.
6. Antibodies Incorporated
7. Trinity Biotech plc
8. Hoffmann-La Roche Ltd
9. Siemens Healthineers AG
10. Corewell Health
11. Abcam Limited
12. GROUP GmbH
13. Immuno Concepts NA Ltd
14. Medical & Biological Laboratories Co., Ltd.
15. Others

Recent Developments

October 2025: Tellgen invested in CytoCares to expand its autoimmune diagnostics capabilities and advanced its “Diagnosis-Therapy-Monitoring” model. The company’s CAP-recognized flow fluorescence platform detected 46 autoantibody targets, including a 16-item ANTINUCLEAR ANTIBODY TEST panel, and aimed to improve early detection, disease stratification, and patient monitoring while accelerating integrated diagnostic-therapy solutions in the growing autoimmune disease landscape.

Segmentation

1. By Product(2026-2034)
   1. Reagents & Assay Kits
   2. Systems
   3. Software & Services
2. By Technique(2026-2034)
   1. ELISA
   2. Immunofluorescence Assay
   3. Multiplex Assay
3. By Application(2026-2034)
   1. Rheumatoid Arthritis
   2. Systemic Lupus Erythematosus
   3. Sjogren’s Syndrome
   4. Scleroderma
   5. Other Diseases
4. By End Use(2026-2034)
   1. Hospitals
   2. Clinical Laboratories
   3. Physician Office Laboratories
   4. Others